Hepatitis B core-related antigen reflects viral replication and protein production in chronic hepatitis B patients

Background:Hepatitis B core-related antigen(HBcrAg)is a promising disease-monitoring marker for chronic hepatitis B(CHB).We investigated correlations between HBcrAg with antiviral efficacy and virological and histological variables.Methods:One hundred and forty-five CHB patients from the mainland of China between August 2013 and September 2016 who underwent liver biopsy received entecavir therapy and had paired liver biopsy at 78 weeks.We analyzed correlations between HBcrAg and virological and histological variables in hepatitis B e antigen(HBeAg)-positive and HBeAg-negative patients.We also explored the predictors of HBeAg loss after 78 weeks of antiviral therapy.Pearson correlation analysis and logistic forward stepwise regression were the main statistic methods.Results:HBeAg-positive patients(n=93)had higher baseline HBcrAg(median 7.4 vs.5.3 log10 U/mL P<0.001)and greater HBcrAg declines(median 1.6 vs.0.9 log10 U/mL P=0.007)than HBeAg-negative patients after 78 weeks of therapy.At baseline,HBcrAg correlated with hepatitis B virus(HBV)DNA in both HBeAg-positive(r=0.641,P<0.001)and-negative patients(r=0.616,P<0.001),with hepatitis B surface antigen(HBsAg)in HBeAg-positive patients(r=0.495,P<0.001),but not with anti-hepatitis B virus core antibody(anti-HBc).Weak correlations existed between HBcrAg,histology activity index(HAI;r=0.232,P=0.025),and Ishak fibrosis score(r=-0.292,P=0.005)in HBeAg-positive patients.At 78 weeks,significant correlations existed only between HBcrAg and anti-HBc in HBeAg-positive(r=-0.263,P=0.014)and HBeAg-negative patients(r=-0.291,P=0.045).Decreased HBcrAg significantly correlated with reduced HBV DNA(r=0.366,P=0.001;r=0.626,P<0.001)and HBsAg(r=0.526,P=0.001;r=0.289,P=0.044)in HBeAg-positive and-negative patients,respectively,and with reduced HAI in HBeAg-positive patients(r=0.329,P=0.001).Patients with HBeAg loss(n=29)showed a larger reduction in HBcrAg than those without(median 2.3 vs.1.3 log10 U/mL,P=0.001).In multivariate analysis,decreased HBcrAg was an independent predictor of HBeAg loss(P=0.005).Conclusions:HBcrAg reflects viral replication and protein production.Decreased HBcrAg could predict HBeAg loss after antiviral therapy.Trial registration:Clinical Trials.gov:NCT01962155;https://www.clinicaltrials.gov/ct2/show/NCT01962155?term=NCT01962155&draw=2&rank=1.